Nisa Investment Advisors Portfolio holdings
AUM
$22.2B
1-Year Return
21.03%
This Quarter Return
+8.93%
1 Year Return
+21.03%
3 Year Return
+95.61%
5 Year Return
+159.15%
10 Year Return
+382.87%
AUM
$12.8B
AUM Growth
+$89.4M
(+0.71%)
Cap. Flow
-$657M
Cap. Flow
% of AUM
-5.15%
Top 10 Holdings %
Top 10 Hldgs %
21.18%
Holding
2,833
New
113
Increased
921
Reduced
935
Closed
132
Top Buys
| 1 |
Linde
LIN
|
+$10.8M |
| 2 |
Tesla
TSLA
|
+$7.91M |
| 3 |
Vanguard Long-Term Corporate Bond ETF
VCLT
|
+$7.03M |
| 4 |
Verizon
VZ
|
+$6.99M |
| 5 |
GE HealthCare
GEHC
|
+$6.42M |
Top Sells
| 1 |
TSMC
TSM
|
+$87.9M |
| 2 |
Vanguard Total Stock Market ETF
VTI
|
+$69.9M |
| 3 |
ASML
ASML
|
+$49.2M |
| 4 |
Baidu
BIDU
|
+$28.5M |
| 5 |
Crown Castle
CCI
|
+$28.5M |
Sector Composition
| 1 | Technology | 23.54% |
| 2 | Healthcare | 12.75% |
| 3 | Financials | 11.56% |
| 4 | Consumer Discretionary | 9.07% |
| 5 | Industrials | 8.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
NGMS
2001
DELISTED
NeoGames S.A. Ordinary Shares
NGMS
| $20K | ﹤0.01% |
1,300
| – | – |
|
|
CPE
2002
DELISTED
Callon Petroleum Company
CPE
| $20K | ﹤0.01% |
605
+20
| +3% | +$661 |
|
|
SBDS
2003
Solo Brands, Inc.
SBDS
$23.2M
| $20K | ﹤0.01% |
2,834
+2,800
| +8,235% | +$19.8K |
|
2004
Akero Therapeutics
AKRO
$3.53B
| $19K | ﹤0.01% |
501
-102,520
| -100% | -$3.89M |
|
2005
Ameresco
AMRC
$1.44B
| $19K | ﹤0.01% |
392
+20
| +5% | +$969 |
|
2006
Cerus
CERS
$236M
| $19K | ﹤0.01% |
6,389
+6,220
| +3,680% | +$18.5K |
|
2007
Cytek Biosciences
CTKB
$504M
| $19K | ﹤0.01% |
2,090
+50
| +2% | +$455 |
|
2008
Lifestance Health
LFST
$2.11B
| $19K | ﹤0.01% |
+2,514
| New | +$19K |
|
2009
Liberty Latin America Class C
LILAK
$1.58B
| $19K | ﹤0.01% |
2,340
| – | – |
|
2010
Pulmonx
LUNG
$68M
| $19K | ﹤0.01% |
1,734
+1,700
| +5,000% | +$18.6K |
|
2011
NewtekOne
NEWT
$305M
| $19K | ﹤0.01% |
1,500
| – | – |
|
2012
Shell
SHEL
$210B
| $19K | ﹤0.01% |
327
| – | – |
|
|
VERV
2013
DELISTED
Verve Therapeutics
VERV
| $19K | ﹤0.01% |
1,331
| – | – |
|
2014
Cable One
CABO
$909M
| $18K | ﹤0.01% |
25
-13,979
| -100% | -$10.1M |
|
2015
CareDx
CDNA
$703M
| $18K | ﹤0.01% |
1,970
+1,630
| +479% | +$14.9K |
|
2016
Daktronics
DAKT
$1.05B
| $18K | ﹤0.01% |
3,180
| – | – |
|
2017
Editas Medicine
EDIT
$243M
| $18K | ﹤0.01% |
2,465
-675
| -21% | -$4.93K |
|
2018
First Merchants
FRME
$2.33B
| $18K | ﹤0.01% |
545
| – | – |
|
2019
Hingham Institution for Saving
HIFS
$602M
| $18K | ﹤0.01% |
79
-110
| -58% | -$25.1K |
|
2020
Hims & Hers Health
HIMS
$11.1B
| $18K | ﹤0.01% |
1,800
+1,690
| +1,536% | +$16.9K |
|
2021
Intrepid Potash
IPI
$382M
| $18K | ﹤0.01% |
+640
| New | +$18K |
|
|
ITOS
2022
DELISTED
iTeos Therapeutics
ITOS
| $18K | ﹤0.01% |
1,291
+1,260
| +4,065% | +$17.6K |
|
2023
Marine Products Corp
MPX
$321M
| $18K | ﹤0.01% |
+1,400
| New | +$18K |
|
2024
Nektar Therapeutics
NKTR
$922M
| $18K | ﹤0.01% |
1,687
+954
| +130% | +$10.2K |
|
2025
ON24
ONTF
$233M
| $18K | ﹤0.01% |
+2,050
| New | +$18K |
|